Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-025452
Filing Date
2020-05-14
Accepted
2020-05-14 16:07:41
Documents
78
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rvmd-10q_20200331.htm 10-Q 2571530
2 EX-10.4 rvmd-ex104_131.htm EX-10.4 307301
3 EX-31.1 rvmd-ex311_9.htm EX-31.1 17972
4 EX-31.2 rvmd-ex312_8.htm EX-31.2 18143
5 EX-32.1 rvmd-ex321_7.htm EX-32.1 8484
6 EX-32.2 rvmd-ex322_6.htm EX-32.2 8535
7 GRAPHIC gebjamx5z3j0000001.jpg GRAPHIC 38193
  Complete submission text file 0001564590-20-025452.txt   9143063

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE DOCUMENT rvmd-20200331.xml EX-101.INS 1973289
9 XBRL TAXONOMY EXTENSION SCHEMA rvmd-20200331.xsd EX-101.SCH 63696
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rvmd-20200331_cal.xml EX-101.CAL 70609
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvmd-20200331_def.xml EX-101.DEF 193068
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvmd-20200331_lab.xml EX-101.LAB 457481
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvmd-20200331_pre.xml EX-101.PRE 343831
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

EIN.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39219 | Film No.: 20877788
SIC: 2836 Biological Products, (No Diagnostic Substances)